8-K: Digital Ally Secures $25M Equity Line, $750K Convertible Note

Digital Ally, Inc. has secured a $25 million committed equity financing facility and an initial $750,000 senior secured convertible note to bolster working capital.

Summary

• Digital Ally, Inc. (DGLY) entered into a Securities Purchase Agreement for an initial $750,000 senior secured convertible note and warrants.
• The note has an original principal amount of $806,451.61, reflecting a 7% original interest discount, and carries an 8% annual interest rate, payable monthly, maturing on September 15, 2026.
• The fixed conversion price for the note is $1.6992, subject to adjustment, with a floor price of $0.36, and the conversion price is 90% of the VWAP over the five trading days immediately preceding the conversion date.
• The company also secured a $25 million committed equity financing facility (ELOC) with Yield Point NY LLC, allowing it to sell shares at its discretion over a 36-month period.
• Under the ELOC, the investor will purchase shares at 92% of the lowest daily trade price during a three-day valuation period.
• A 3.0% commitment fee on the $25 million ELOC will be paid partly in shares (19.99% of outstanding shares) and partly in cash (30% of proceeds from subsequent financings, including the ELOC).
• The company reimbursed the ELOC investor $30,000 for legal fees.
• A second closing for an additional $250,000 in notes and warrants is contingent on the effectiveness of the registration statement covering the resale of the shares.

Sentiment

Score: 3

Explanation: While the company secured significant financing, the terms are highly dilutive and costly, reflecting a challenging capital-raising environment. The discounts on conversion/purchase prices, commitment fees, and potential liquidated damages for registration delays indicate a less favorable position for existing shareholders. The ELOC provides flexibility but at a high potential cost in terms of dilution.

Positives

• Secured $750,000 in immediate gross proceeds from the convertible note, providing working capital.
• Established a flexible $25 million committed equity financing facility (ELOC) for future capital needs, allowing the company to draw capital at its sole discretion.
• The convertible note is senior to most outstanding and future indebtedness of the company and its subsidiaries (with specific exceptions), enhancing its security for the investor.
• The company has the option to prepay the convertible note at 110% of the outstanding principal plus accrued interest.
• The company can elect to pay monthly redemptions in conversion shares, preserving cash.

Negatives

• The convertible note was issued at a 7% original interest discount, meaning the company received $750,000 for a $806,451.61 principal amount.
• The conversion price for the note is at a 10% discount to VWAP, and ELOC shares are purchased at 92% of the lowest daily trade price, both highly dilutive terms for existing shareholders.
• A 3.0% commitment fee on the $25 million ELOC, partially paid in shares, will cause further dilution and represents a significant cost of capital.
• The company reimbursed the ELOC investor $30,000 for legal fees, reducing net proceeds from the financing.
• Liquidated damages of 2% of the original principal amount of the notes per month are payable for delays in filing or achieving effectiveness of the registration statement.
• The ELOC has an Exchange Cap of 345,311 shares (19.99% of outstanding shares prior to the agreement) without stockholder approval, potentially limiting access to the full $25 million facility.
• The company is restricted from certain 'Variable Rate Transactions' and other equity issuances during the ELOC term, which could limit future financing flexibility.
• The investor is restricted from short selling or hedging transactions establishing a net short position with respect to the common stock during the term, which could impact market liquidity or price discovery.

Risks

• Dilution Risk: The conversion of notes and exercise of warrants, especially at discounted prices (90% of VWAP for notes, 92% of lowest daily trade price for ELOC shares), along with the commitment fee paid in shares, could substantially dilute existing shareholders.
• Market Price Volatility: The conversion and purchase prices are tied to VWAP, meaning more shares would be issued if the stock price declines, exacerbating dilution.
• Liquidity Risk: The Leak-Out Agreement limits the holder's ability to sell more than 20% of the composite daily trading volume, potentially impacting the market's ability to absorb large share issuances.
• Regulatory Compliance Risk: Failure to file registration statements or maintain effectiveness could result in liquidated damages (2% of principal per month) and other penalties.
• Financial Covenants/Events of Default: The notes and security agreements contain numerous events of default (e.g., payment defaults, breach of covenants, bankruptcy events, delisting, failure to maintain public information, monetary judgments over $250,000), which could trigger acceleration of debt.
• Subsequent Financing Restrictions: Restrictions on incurring senior or secured indebtedness without consent, and limitations on certain equity issuances (Variable Rate Transactions), could limit future financing options.
• Shareholder Approval Risk: The Exchange Cap for the ELOC requires shareholder approval for issuances exceeding 19.99% of outstanding shares, which if not obtained, limits the facility.
• Subsidiary Guarantees: Most subsidiaries (except Digital Ally Healthcare, Inc. and Nobility Healthcare, LLC) have guaranteed the obligations, potentially exposing them to the company's debt.
• Intellectual Property Security: The company's intellectual property is pledged as collateral, a critical asset.

Future Outlook

The company has secured significant financing to support its working capital and future operations. The ELOC provides a flexible funding mechanism, allowing the company to draw capital as needed over a 36-month period, contingent on market conditions and regulatory approvals. The company intends to use the proceeds for working capital and will disclose specific uses in future prospectuses.

Management Comments

• The company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions.
• The company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the company.
• The company will use its reasonable best efforts to obtain the stockholder approval to issue such number of shares of its Common Stock in excess of the Exchange Cap as may be necessary.
• The company believes that its relationships with its employees are good.

Industry Context

This financing structure, involving a convertible note and an equity line of credit, is common for smaller public companies seeking flexible capital without the immediate dilution or stringent covenants of traditional debt or equity offerings. The terms, particularly the discounts to market price for conversions/purchases and the commitment fees, reflect the cost of capital for companies in this market segment, often indicating a need for funding that traditional sources might not provide on favorable terms. The restrictions on 'Variable Rate Transactions' aim to protect the current investor from further dilutive financing structures.

Comparison to Industry Standards

• The 7% discount on the convertible note and the 8% interest rate are within the typical range for secured convertible debt for companies of similar market capitalization and risk profile, though the discount is on the higher side.
• The 92% of lowest daily trade price for ELOC purchases is a common pricing mechanism for such facilities, designed to provide the investor with a discount to market, but it is highly dilutive for existing shareholders.
• The 3.0% commitment fee for the ELOC is standard for a facility of this size and duration.
• The 19.99% Exchange Cap without shareholder approval is a standard Nasdaq listing rule, indicating the company is operating within typical regulatory constraints for such transactions.
• The liquidated damages for registration statement delays (2% per month) are a common protective measure for investors in these types of financings, ensuring timely liquidity for their shares.

Corporate Governance

Related Party Transactions

• The company is restricted from repaying, repurchasing, or acquiring indebtedness held by any Related Party or Affiliate.
• The company is restricted from entering into any transaction with any Affiliate or Related Party without prior written consent of the Purchasers, with exceptions for employee/executive/director compensation approved by the Compensation Committee.

Stakeholder Impact

• Shareholders: Significant potential for dilution due to discounted conversion/purchase prices for the notes and ELOC shares, as well as the commitment fee paid in shares. Existing shareholders' voting power and economic interest could decrease.
• Creditors: The Senior Secured Convertible Note ranks senior to most outstanding and future indebtedness, potentially impacting the recovery prospects of other unsecured creditors in a default scenario.
• Employees/Management: No direct impact mentioned, but the financing provides working capital which could support ongoing operations and stability. Restrictions on equity compensation are noted but with exceptions for board-approved plans.
• Customers/Suppliers: No direct impact mentioned, but improved financial stability from the capital raise could indirectly benefit relationships.

Next Steps

• Company to file a Current Report on Form 8-K disclosing the agreements by September 17, 2025.
• Company to file a Form D with respect to the issuance and sale of shares under Regulation D within 15 calendar days of the Closing Date.
• Company to prepare and file an Initial Registration Statement covering the resale of shares from the Notes and Warrants within 30 business days of the First Closing.
• Company to use best efforts to cause the Initial Registration Statement to be declared effective within 60 calendar days of its filing.
• Company to file a final Prospectus with the Commission by 9:30 a.m. (New York City time) on the Trading Day after the effective date of the Registration Statement.
• Company to consummate a second closing of an additional $250,000 of Notes and Warrants within two business days from the effectiveness date of the registration statement.
• Company to obtain shareholder approval for issuing shares in excess of the 19.99% Exchange Cap under the ELOC, if necessary.
• Company to maintain the listing and trading of its Common Stock on the Nasdaq Capital Market or another Eligible Market.
• Company to make all required security filings with the United States Patent and Trademark Office and the U.S. Copyright Office within a reasonable period.

Key Dates

Recommendation

The terms of this financing are highly unfavorable and indicative of a company in a distressed capital position. The significant discounts on the convertible note (7% original discount, 10% conversion discount to VWAP) and the ELOC (8% discount to lowest daily trade price) will lead to substantial dilution for existing shareholders. The 3% commitment fee on the $25 million ELOC, partially paid in shares, further exacerbates this dilution. The company's agreement to pay liquidated damages for registration delays and the numerous events of default in the note and security agreements highlight the high risk associated with this investment. The restrictions on future financings and the need for shareholder approval for the full ELOC amount also present operational and financial hurdles. These terms suggest a desperate need for capital at any cost, which is a strong negative signal for the company's financial health and future prospects. Investors should consider exiting their positions due to the severe dilutive impact and the underlying financial distress implied by these terms.

Keywords

Digital Ally, DGLY, Convertible Note, Equity Line of Credit, ELOC, Secured Financing, Warrants, Dilution, SEC Filing, Capital Raise, Corporate Finance, Investment, Securities Purchase Agreement, Registration Rights, Risk Management